Challenges in Pharmacovigilance
This session of the Biosimilars 2020 will be looking into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.
- Role of Pharma Industries in the Improvement of Pharmacovigilance System
- Current Problems in Biosimilar Pharmacovigilance
- Detection and Evaluation of Drug Safety Signals
- Pharmacoepidemiology and GMP